EHA 2021 | Managing the progression of MDS to AML
Andrew Brunner
• 3 Jun 2021
Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, talks on the management of progression from myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML), highlighting the impact of having received previous hypomethylating agents (HMAs). Dr Brunner discusses the poor response of patients who progress to AML from MDS and have received HMA therapy prior to induction therapy, and gives an overview of alternative approaches. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrew M. Brunner, MD, has participated in consultancy work for Novartis, Acceleron, Agios, BMS/Celgene and Takeda.
